StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN) stock

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$945.53−12.23 (-1.28%)

Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –

Regeneron Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Regeneron Pharmaceuticals's gross profit for the twelve months ending Mar 31, 2018 was $5.85B, up 21.9% year over year. For fiscal 2019 it was $6.15B, up 25.4% from the year before. Over ten years it grew 32.2% a year on average. The highest annual figure on record is $6.15B in fiscal 2019.

Annual gross profit

PeriodPeriod endValueChange
FY2019Dec 31, 2019$6.15B+25.4%
FY2018Dec 31, 2018$4.91B-13.4%
FY2017Dec 31, 2017$5.67B+21.5%
FY2016Dec 31, 2016$4.67B+20.8%
FY2015Dec 31, 2015$3.86B+43.5%
FY2014Dec 31, 2014$2.69B+35.4%
FY2013Dec 31, 2013$1.99B+53.5%
FY2012Dec 31, 2012$1.29B+193.1%
FY2011Dec 31, 2011$441.61M-3.4%
FY2010Dec 31, 2010$456.98M+21.0%
FY2009Dec 31, 2009$377.58M+59.0%
FY2008Dec 31, 2008$237.53M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2018Mar 31, 2018$1.44B+14.7%
Q4 FY2017Dec 31, 2017$1.53B+29.4%
Q3 FY2017Sep 30, 2017$1.45B–
Q2 FY2017Jun 30, 2017$1.43B–
Q1 FY2017Mar 31, 2017$1.26B–
Q4 FY2016Dec 31, 2016$1.18B–

More Regeneron Pharmaceuticals figures

See a number that looks wrong?